A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas

Trial Profile

A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Fluorouracil (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
    • 19 Mar 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
    • 24 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top